Description
Prostate cancer is a global health challenge. Many patients with prostate cancer have positive outcomes, but some patients develop aggressive tumours that require ongoing treatment. Tumours eventually develop drug resistance to currently available treatments, so new therapeutic options are required.
Current clinical trials are testing a new approach where patients are given monthly injections of testosterone. So far, the results are promising, but some tumours are more sensitive to this treatment than others.
Our goal is to increase the effectiveness of hormone treatments so that more patients benefit from them.
These studies use patient-derived models, such as xenografts and 3D cultures of organoids, to compare the features of sensitive and resistant tumours and measure their responses to candidate drug treatments. Other techniques may include immunohistochemistry, quantitative PCR and bioinformatics.
We do this work in collaboration with other scientists, clinicians and patient advocates.
Essential criteria:
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords
cancer, organoids, endocrinology, hormones, Department of Anatomy and Developmental Biology, therapeutics, drugs
School
Biomedicine Discovery Institute (School of Biomedical Sciences) » Anatomy and Developmental Biology
Available options
PhD/Doctorate
Masters by research
Honours
Time commitment
Full-time
Top-up scholarship funding available
No
Physical location
Biomedicine Discovery Institute
Co-supervisors
Prof
Gail Risbridger
Assoc Prof
Renea Taylor